Literature DB >> 17989129

Improving state pain policies: recent progress and continuing opportunities.

Aaron M Gilson1, David E Joranson, Martha A Maurer.   

Abstract

The National Institutes of Health reports that 100 million Americans suffer from chronic pain, including pain associated with the disease of cancer. Painful conditions can strike anyone, including cancer patients and cancer survivors. Unrelieved severe pain can limit a person's functioning and sometimes even destroy the will to live. When the quality of pain relief provided is inadequate, it is usually the result of failures to apply existing knowledge about pain and its treatment, including the appropriate use of opioids. But pain relief also can be affected by the regulatory environment and fear of being investigated for excessive prescribing. The importance of evaluating and improving policies governing pain management has been recognized by national and international authorities, including the Institute of Medicine and the World Health Organization. A pilot examination of state laws and regulatory policies demonstrated that they contained a number of outdated medical concepts and prescribing restrictions and did not contain key elements of law that can make pain management a priority for licensed medical practitioners. The Pain & Policy Studies Group developed a research program to evaluate US federal and state policy governing the medical use of pain medication. This article describes 3 national policy evaluations and how the results are being used to document improvements in state pain policies. An emerging role for clinicians and their professional organizations to improve their state's pain policies is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989129     DOI: 10.3322/CA.57.6.341

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  9 in total

Review 1.  Unrelieved pain: a crisis.

Authors:  Barry Sessle
Journal:  Pain Res Manag       Date:  2011 Nov-Dec       Impact factor: 3.037

2.  Behavioral medicine: a voyage to the future.

Authors:  Francis J Keefe
Journal:  Ann Behav Med       Date:  2011-04

3.  Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report.

Authors:  Jung Hye Kwon; Sung Yong Oh; Gary Chisholm; Jung-Ae Lee; Jae Jin Lee; Keon Woo Park; Seung-Hyun Nam; Hun Ho Song; Keehyun Lee; Dae Young Zang; Ho Young Kim; Dae Ro Choi; Hyo Jung Kim; Jung Han Kim; Joo Young Jung; Geundoo Jang; Hyeong Su Kim; Ji Yun Won; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

4.  Experience of barriers to pain management in patients receiving outpatient palliative care.

Authors:  Jung Hye Kwon; David Hui; Gary Chisholm; Woo Taik Hong; Linh Nguyen; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-06-12       Impact factor: 2.947

5.  The pain crisis: what it is and what can be done.

Authors:  Barry J Sessle
Journal:  Pain Res Treat       Date:  2012-09-19

6.  Opioid rotation with extended-release opioids: where should we begin?

Authors:  Srinivas Nalamachu
Journal:  Int J Gen Med       Date:  2011-12-30

7.  A survey on doctors' knowledge and attitude of treating chronic pain in three tertiary hospitals in Nigeria.

Authors:  Emmanuel O Sanya; Philip M Kolo; Muhammadu A Makusidi
Journal:  Niger Med J       Date:  2014-03

8.  Psychometric evaluation of the Chinese version of the revised American Pain Society Patient Outcome Questionnaire concerning pain management in Chinese orthopedic patients.

Authors:  Huan Fang; Jingjuan Liang; Zhen Hong; Kenji Sugiyama; Takao Nozaki; Susumu Kobayashi; Tetsuro Sameshima; Hiroki Namba; Tetsuya Asakawa
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

9.  Knowledge, attitudes and barriers of physicians, policy makers/regulators regarding use of opioids for cancer pain management in Thailand.

Authors:  Pornsuree Srisawang; Md Harun-Or-Rashid; Tomoya Hirosawa; Junichi Sakamoto
Journal:  Nagoya J Med Sci       Date:  2013-08       Impact factor: 1.131

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.